APA (7th ed.) Citation

VD, S., NG, S. G., LD, P., SH, K., S, B., SK, P., . . . PK, S. (2023). The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator. Frontiers in pharmacology, 14, 1135952. https://doi.org/10.3389/fphar.2023.1135952

Chicago Style (17th ed.) Citation

VD, Shiragannavar, Sannappa Gowda NG, Puttahanumantharayappa LD, Karunakara SH, Bhat S, Prasad SK, Kumar DP, and Santhekadur PK. "The Ameliorating Effect of Withaferin A on High-fat Diet-induced Non-alcoholic Fatty Liver Disease by Acting as an LXR/FXR Dual Receptor Activator." Frontiers in Pharmacology 14 (2023): 1135952. https://doi.org/10.3389/fphar.2023.1135952.

MLA (9th ed.) Citation

VD, Shiragannavar, et al. "The Ameliorating Effect of Withaferin A on High-fat Diet-induced Non-alcoholic Fatty Liver Disease by Acting as an LXR/FXR Dual Receptor Activator." Frontiers in Pharmacology, vol. 14, 2023, p. 1135952, https://doi.org/10.3389/fphar.2023.1135952.